Introduction: With dialysis delivery systems that operate at low dialysate flow rates, prescriptions for more frequent hemodialysis (HD) employ dialysate volume as the primary parameter for small solute removal rather than blood-side urea dialyzer clearance (K). Such delivery systems, however, yield dialysate concentrations that almost completely saturate with blood (water), suggesting that the volume of urea cleared (the product of K and treatment time or Kt) can be readily estimated from the prescribed dialysate volume to target small solute removal. Methods For more frequent HD, we examined the volume of urea cleared per treatment required to achieve a minimal dose of small solute removal, comparing results based on body surface area (BSA) with those based on KDOQI clinical practice guidelines, that is, a weekly stdKt/V of 2.1. Estimates of the target volume of urea cleared were calculated for 4, 5, and 6 treatments per week, and compared for patients with different anthropometric estimates of total body water volume (V ant ). BSA was assumed proportional to V ant 0.8 , and residual kidney function was neglected.
INTRODUCTION
Prescriptions for more frequent hemodialysis (HD) differ from those for conventional thrice-weekly therapy, partly because of the additional options available to fit individual patient lifestyles. The added complexity is apparent when prescribing more frequent HD to achieve a minimal dose of small solute removal. Treatment frequency here is a significant determinant of urea standard weekly Kt/V (stdKt/V), 1 and the target dose is a value for an entire week rather than a single treatment. While there are equations for calculating weekly stdKt/V from the HD prescription and the achieved treatment dose (single-pool or equilibrated Kt/V), [1] [2] [3] they are not always easy to use in clinical practice. Simpler methods to help clinicians prescribe the dose of small solute removal during more frequent HD are desirable.
Some delivery systems used for more frequent HD employ dialysate flow rates less than the conventional 500 mL/min and require significantly less dialysis fluid. [4] [5] [6] [7] When dialysate flow rates are less than 200 mL/min, the dialyzer clearance of urea approaches the dialysate flow rate (as long as a high flux/efficiency dialyzer is used and blood flow rates are high). Figure 1 shows an example relationship between the dialysate-toplasma (more accurately, blood water) concentration ratio of urea (D/P) and dialysate flow rates less than 500 mL/min for a dialyzer with an estimated in vivo urea K o A of 650 mL/min at a dialysate flow rate of 500 mL/min; theoretical predictions are shown for various blood flow rates. When urea D/P approaches unity, the dialyzer clearance of urea approaches the dialysate flow rate (dialyzer clearance of urea = dialysate flow rate × urea D/P). At a dialysate flow rate of 200 mL/min and a blood flow rate of 400 mL/min, dialyzer clearance of urea is minimally 85% of the dialysate flow rate; at a dialysate flow rate of 120 mL/min, clearance is minimally 90% of that rate. Because treatment time can be reliably determined, such systems allow a simple estimate of the product of dialyzer clearance of urea (K) times treatment time (t), or Kt per treatment; this product is the volume of blood cleared of urea during the treatment. 11 It is thus possible to estimate a minimal dose of small solute removal during more frequent HD, as we show in this report.
For prescriptions of more frequent HD using delivery systems with low dialysate flow, we explore two approaches for using estimates of the volume of urea cleared to provide minimal dose targets of small solute removal. In the first, the target volume of urea cleared is calculated based on a minimum weekly stdKt/V of 2.1, as suggested in KDOQI clinical practice guidelines. 12 In the second, we use the approach reported by Lowrie et al. 13, 14 for determining a target volume of urea cleared as a function of body surface area (BSA), and extend it from thrice-weekly HD to prescriptions of more frequent HD.
METHODS
The relationship used in this work between treatment Kt/V and weekly stdKt/V was previously described as
where N is the number of treatments per week and t is treatment time in hours. It is recognized that Equation 1 is only an approximation and provides an underestimate of stdKt/V. Work by others 2 has shown that more accurate estimates of stdKt/V can be obtained by accounting for both weekly fluid removal and residual kidney function; however, the approach described here applies in principle to these more complex equations. For present Figure 1 The dialysate-to-plasma (more accurately, blood water) concentration ratio of urea (D/P) plotted vs. dialysate flow rate (Q d ) for a dialyzer with an in vivo urea mass transfer-area coefficient (K o A) of 650 mL/min at a Q d of 500 mL/min. Urea K o A was assumed to decrease with Q d between 500 and 350 mL/min according to a published equation 8 ; urea K o A values (in mL/min) for Q d less than 200 mL/min were assumed equal to 62 + 2.4 × Q d . 9 Urea K o A values for Q d between 200 and 350 mL/min were linearly interpolated. All urea D/P values at various blood flow rates were calculated using the classical equation of Michaels. 10 The solid line indicates a blood flow rate of 300 mL/min, the short dashed line a blood flow rate of 400 mL/min, and the long dashed line a blood flow rate of 500 mL/min. purposes, the use of Equation 1 will predict conservative estimates of volume of urea cleared to achieve minimal targets. It should be emphasized that the more accurate equation 2 should be used to measure dialysis dose in clinical practice, if the additional data are available as recommended in clinical practice guidelines. 12 To apply KDOQI clinical practice guidelines, the lefthand side of Equation 1 can be set equal to 2.1 and the resulting equation can be solved implicitly for Kt/V for a given N and t. With this value of Kt/V, the volume of urea cleared per treatment (Kt) can be calculated for any patient with a given urea distribution volume V; this treatment Kt will be referred to as the target volume of urea cleared based on KDOQI.
To determine the volume of urea cleared per treatment based on BSA, stdKt/V is not arbitrarily set equal to 2.1 in Equation 1 . Instead, we use the relationship between the target volume of urea cleared per treatment (Kt) and BSA for patients treated by conventional thrice-weekly HD to minimize patient mortality risk reported by Lowrie et al. 13 ; this relationship is plotted in Figure 2 . The results in this figure were transformed into a relationship between a target weekly stdKt value and an anthropometric estimate of total body water (V ant ) using the following assumptions and calculations. BSA (in m 2 ) was assumed equal to 0.
, representative of that reported for males and female patients in the HEMO Study 15 ; that relationship can be used to convert BSA in the abscissa of Figure 2 to values of V ant . And the target Kt values in Figure 2 were substituted into Equation 1 to calculate weekly stdKt (weekly stdKt/V × V) where V is assumed to be 85% of V ant . 16 Figure 3 displays weekly stdKt values calculated using this method for patients treated by conventional thrice-weekly HD.
Weekly stdKt values shown in Figure 3 were then assumed to provide a minimal dose of small solute removal for patients treated with more frequent HD. To determine the target volume of urea cleared during more frequent HD prescriptions for a patient with an arbitrary V ant , the target Kt was calculated implicitly from the corresponding weekly stdKt value in Figure 3 and Equation 1 using the prescribed treatment parameters N and t; this value will be referred to as target volume of urea cleared based on BSA.
HD prescriptions for three treatments per week were considered for a treatment time of 4 hours, four treatments per week for a treatment time of 3.5 hours, and five and six treatments per week for a treatment time of 3 hours. Target volumes of urea cleared were rounded up to the nearest L. All results are reported as a function of V ant , and residual kidney function was neglected.
This was a theoretical study that only included computer-simulated, not actual, patients; thus, it was not necessary to consider whether ethical standards of human experimentation were followed, such as those in accord with the Declaration of Helsinki and its revisions. Accordingly, it was also not necessary to obtain informed consent as no actual subjects were involved in this work.
RESULTS
To first check the consistency of the current approach for calculating target volumes of urea cleared per treatment with the results from Lowrie et al., 13 Kt values based on KDOQI and those based on BSA were compared for conventional thrice-weekly HD ( Figure 4) . As expected based on previous work, [17] [18] [19] [20] the volumes of urea cleared based on BSA were, for small patients, larger than those based on KDOQI, while the reverse was true for large patients. Target volumes of urea cleared based on BSA normalized by patient V ant in the current study are somewhat larger, and therefore more conservative, than those reported by Lowrie et al. 13 It should be emphasized that these rather large target volumes of urea cleared for conventional thrice-weekly HD are not applicable to dialysis delivery systems at low dialysate flow rates for the treatment times considered in this report. Figures 5-7 compare target volumes of urea cleared per treatment based on BSA to those based on KDOQI for HD prescriptions of 4, 5, and 6 treatments per week, respectively. The target volume of urea cleared per treatment was lower with more frequent treatments in a given week. Independent of treatment frequency, and as before, target volumes of urea cleared based on BSA were larger, for small patients, than those based on KDOQI, while the reverse was true for large patients. This pattern is like that observed for patients treated with conventional thrice-weekly HD.
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DISCUSSION
This report shows that a minimal dose of small solute removal for more frequent HD prescriptions can be simply evaluated if the volume of urea cleared per treatment is known or can be estimated. It remains unclear whether target volumes of urea cleared based on KDOQI-that is, a weekly stdKt/V-or those based on BSA should be preferred; indeed, others have even suggested that such targets should instead be normalized for various metabolic costs. [21] [22] [23] [24] A conservative approach may be to base target volumes on BSA for small patients, and use KDOQI clinical practice guidelines for large patients, although such judgments are not consistent with all available evidence 25 nor supported by hard clinical evidence. 12 It should be noted that the calculated target volumes of urea cleared are not gender-specific as suggested in some studies 20, 26 ; however, prescriptions independent of gender are consistent with the minimal doses recommended by KDOQI Figure 4 Target volume of urea cleared (Kt) per treatment (nearest L) plotted for conventional thrice-weekly hemodialysis prescriptions as a function of patient total body water, based on body surface area (BSA) (white bars) and KDOQI (black bars). Treatment time was assumed to be 4 hours. guidelines and the results from Lowrie et al. 13 The results from the current study allow clinicians to calculate alternative targets for volume of urea cleared by simply referring to (Note that these estimates are only strictly valid for the treatment times assumed in this report; for long nocturnal treatments, the volume of urea cleared may be modestly smaller.)
The Frequent Hemodialysis Network has recognized the potential for using BSA to normalize more frequent HD prescriptions, and devised a novel dose measure, the surface-area-normalized (standard) Kt/V (SAN-stdKt/V). 15 That dose measure is most useful when routinely measuring predialysis and postdialysis serum urea concentrations to calculate Kt/V per treatment; the approach assumes that one cannot make independent assessments of Kt and V separately, but only the ratio Kt/V. Volumes of urea cleared calculated to achieve a SAN-stdKt/V of 2.1 are in very good agreement with those derived from the work of Lowie et al. 13 based on BSA in the current report (results not shown); thus, these approaches are likely to be clinically equivalent.
The current approach is clinically suitable when there is an independent and direct measurement (or close approximation) of dialyzer urea clearance, volume of urea cleared (Kt) determined from the volume of dialysate used, and dialysate saturation of urea. For dialysis delivery systems operating at low dialysate flow rates, the total volume of dialysate to be used per treatment can be conservatively estimated as Kt divided by 0.85-0.90; the results shown in Figures 5-7 are thus easy to implement clinically. To use the calculated results in Figures 5-7 , one must first determine V ant for a given patient; this may be estimated by a fraction (say 45%-60%) of body weight or using the equations of Watson et al. 27 Then, for example, it can be calculated that a 30 L dialysate volume per treatment delivered at low dialysate flow rates Figures 5-7 , such a prescription is predicted to achieve a stdKt/V of 2.1 for patients with a V ant of 30 L treated four times per week, a V ant of 45 L treated five times per week, or a V ant of 55 L treated six times per week. Note that this simple approach can be applied when the volume of urea cleared is prescribed based on either KDOQI guidelines or BSA. For conventional dialysis delivery systems that offer online measurement of dialyzer urea clearance, the volumes of urea cleared shown in Figures 5-7 can be directly targeted during more frequent HD, as has been previously demonstrated during conventional thrice-weekly HD. 14, 28 The limitations of the current work are several. First, it is theoretical and an extrapolation of previous work regarding patients treated by conventional thrice-weekly HD. The use of BSA is, however, grounded in the same approach as that used in the KDOQI guidelines for more frequent HD, that is, using Equation 1. Second, patient BSA was assumed to depend on the anthropometric estimate of total body water volume to the power 0.8; this was a compromise between separate relationships reported for male and female HD patients. 15 We assumed an exponent of 0.8 also because its use would provide more conservative estimates of volume of urea cleared than either the theoretical value of 2/3 or the universal scaling factor of 0.75. 25, 29 Third, it was assumed that the urea distribution volume was 85% of an anthropometric estimate of total body water volume (V ant ); this assumption was based on urea kinetic modeling results from the HEMO Study 16 when V ant was estimated using the equations of Watson et al. 27 Although this assumption may not be valid for all patient populations, it is well known that the urea distribution volume is overestimated by the equations of Watson et al. The recent results from Noori et al. suggest that the urea distribution volume or total body water volume averaged 87% of that predicted by the equations of Watson et al for all patients studied, but could be between 84% and 88% for various patient subgroups. 30 Fourth, as described above, the current approach is not likely beneficial for dialysis delivery systems that do not permit an independent evaluation of dialyzer clearance of urea. Fifth, we note that measures of equivalent continuous clearance and dialysis dose of small solute removal other than stdKt and stdKt/V have been previously proposed, [31] [32] [33] but there is little clinical evidence that they are preferred over those used in this report.
In addition, the current approach does not account for all details of urea kinetics. Equation 1 is only strictly valid for HD treatments equally spaced during a given week. This assumption will result in small calculation errors when considering an average weekly HD prescription, and is less significant when treatments are prescribed more frequently than thrice-weekly. The neglect of postdialysis urea rebound is another concern because it remains important during more frequent HD treatments, 3 Debowska et al. 34 have calculated that neglecting post-dialysis rebound of urea, that is, using a one-compartment instead of a twocompartment urea kinetic model, could result in at most a 20% overestimation of the dose of small solute removal. Alternatively, use of Equation 1, neglecting fluid removal during HD treatments, leads to an approximately 7% underestimate of the dose. 12 Note also that all reported volumes of urea cleared were also rounded up to the nearest L. The sum total of all these assumptions is difficult to assess, but they are reasonable and result in a very simple paradigm that can be easily implemented clinically. It is noted that there are alternative, but more complex, prescription tools available on various websites (such as ureakinetics.org and dosingcalculator.nxstage.com). We can compare predictions from the current study with those reported for patients treated six times per week at home using the NxStage System One (NxStage Medical, Lawrence, MA, USA). 35 These patients had an average body weight of 81 kg, and used 20 L of dialysate at low dialysate flow rates. If one estimates their total body water volume as 40-45 L, the results in Figure 7 would suggest a target volume of urea cleared based on KDOQI, of 18-20 L. This target would require approximately 20-23 L (18-20 L divided by 85%-90%) of dialysate volume per treatment, similar to that previously reported to achieve a weekly stdKt/V of 2.3. 35 Lastly, focusing only on small solutes to determine therapy targets likely underrepresents the removal of other toxins achieved when dialysate flow rates are low. With more frequent HD prescribed on a weekly basis, the total time for toxin removal is supplemented by greater dialysate saturation of middle molecules not achieved in conventional thrice-weekly HD, where dialysate flow rates are 500-800 mL/min. Further research needs to explore how middle molecules, particularly phosphorus, are removed in such systems. 36 It may even be clinically advantageous to prescribe more frequent HD treatments based on a standard Kt (also called the equivalent continuous clearance) for phosphorus, as suggested recently by others. 37, 38 In summary, the current report describes how to use the volume of urea cleared to provide quantitative predictions, adjusting for patient body size, to achieve a minimal dose of small solute removal when prescribing more frequent HD. Other aspects of dialysis adequacy require additional considerations, particularly when dialysate flow rates are reduced and attendant solute saturation is increased over a week's worth of therapy.
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